LAVA intents to delist from Nasdaq (LVTX:NASDAQ) LAVA Therapeutics announces 87% shares tendered for XOMA acquisition; delisting planned.

LAVA intents to delist from Nasdaq

#lvtx

Origin | Interest | Match

LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq LAVA Therapeutics (Nasdaq: LVTX) announced that 22,877,463 common shares — about 87% of outstanding shares — were validly tendered and not withdrawn by the initial offer deadline of one minute after 11:59 p.m. ET on November 12, 2025.The minimum tender condition for XOMA Royalty Corporation's acquisition offer has been satisfied and tendered shares are expected to be accepted for payment on or about November 13, 2025. A subsequent offering period runs through one minute after 11:59 p.m. ET on November 20, 2025 (shares tendered then cannot be withdrawn).LAVA expects its Nasdaq trading to be suspended prior to market open on or about November 21, 2025, and expects Nasdaq to file a removal notification with the SEC on or about November 24, 2025. Completion remains subject to conditions in XOMA Royalty's Schedule TO.

#LVTX LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq

www.stocktitan.net/news/LVTX/lava-announces...

LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline LAVA Therapeutics (NASDAQ: LVTX) reminded shareholders to tender shares for the proposed sale to XOMA Royalty (NASDAQ: XOMA) before the Offer expiration at one minute after 11:59 p.m. ET on November 12, 2025. XOMA and LAVA entered a share purchase agreement on August 4, 2025, and XOMA extended its Offer on October 17, 2025.The LAVA Board unanimously recommends tendering. The notice warns that if the required shares are not tendered the Offer cannot close, potentially exposing shareholders to liquidation with proceeds likely lower than the Offer cash consideration and to a possible share-price decline. Instructions and broker contact details are provided for tendering and questions.

#LVTX LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline

www.stocktitan.net/news/LVTX/lava-therapeut...

LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update LAVA Therapeutics (NASDAQ: LVTX) has announced significant developments in Q2 2025, headlined by a definitive agreement to be acquired by XOMA Royalty Corporation. The acquisition terms include $1.16-$1.24 per share in cash, plus contingent value rights tied to LAVA's partnered and unpartnered programs, with closing expected in Q4 2025.The company reported Q2 2025 financial results with cash position of $56.2 million as of June 30, 2025, down from $76.6 million at year-end 2024. Net loss increased to $8.6 million ($0.32 per share) compared to $8.3 million ($0.31 per share) in Q2 2024. Additionally, LAVA announced the discontinuation of its LAVA-1266 program for acute myeloid leukemia and myelodysplastic syndrome.Two partnered programs continue to progress: J&J's JNJ-89853413 in Phase 1 trials for AML/MDS, and Pfizer's PF08046052 for advanced solid tumors.

#LVTX LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/LVTX/lava-reports-s...

Halper Sadeh LLC Launches Investigation Into SCS, LVTX, and ENZB for Shareholders' Rights Halper Sadeh LLC is conducting inquiries into Steelcase Inc., LAVA Therapeutics N.V., and Enzo Biochem, Inc. to ensure the protection of shareholders' rights regarding potential legal violations.

Halper Sadeh LLC Launches Investigation Into SCS, LVTX, and ENZB for Shareholders' Rights #United_States #New_York #Halper_Sadeh_LLC #SCS #LVTX

LAVA Therapeutics Slashes 30% Workforce, Closes Netherlands Operations Amid Strategic Review Biotech reports $66.6M cash position, implements major restructuring with 30% workforce reduction. Strategic alternatives under evaluation. See full impact.

#LVTX LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

www.stocktitan.net/news/LVTX/lava-reports-f...

A black and white photo of a modern storefront with "DONUT" spelled out in large block letters near the top.

#LonelyDonut 04.09.2025
Lewisville, TX
#LewisvilleTX #LVTX #Blackandwhite #bnw #sonyalpha #photography

LAVA Therapeutics Strengthens Balance Sheet: Secures Complete Waiver of $5.1M Debt Biotech firm receives full waiver of $5.1M RVO Innovation Credit debt, strengthening financial position amid strategic review. See impact on balance sheet.

#LVTX LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

www.stocktitan.net/news/LVTX/lava-therapeut...

LAVA Therapeutics Slashes Workforce 30% While Securing $12M in Big Pharma Milestone Payments Revenue surges 76% to $12M with $76.6M cash runway into 2027. Strategic restructuring and milestone payments from J&J and Pfizer strengthen financial position.

#LVTX LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

www.stocktitan.net/news/LVTX/lava-reports-f...

A black and white photo of a pigeon about to land near several other pigeons on a grass island in a parking lot.

#DailyPigeon 03.18.2025
#Blackandwhite #bnw #sonyalpha #photography #LewisvilleTX #LVTX #pigeon

Can LAVA Therapeutics Find a Buyer? Company Cuts 30% of Staff While Exploring Strategic Options Biotech firm implements cost-cutting while continuing Phase 1 trials and pharma partnerships. $76.6M cash position reported as company explores sale options.

#LVTX LAVA Announces Evaluation of Strategic Options

www.stocktitan.net/news/LVTX/lava-announces...

LAVA Therapeutics Initiates Phase 1 Trial for Novel Leukemia Treatment LAVA-1266 LAVA Therapeutics begins clinical testing of CD123-targeted Gammabody® therapy for acute myeloid leukemia, showing promise with reduced off-target effects in preclinical studies.

#LVTX LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

www.stocktitan.net/news/LVTX/lava-doses-fir...

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027 LAVA Therapeutics announced a strategic pipeline reprioritization focusing on LAVA-1266 for hematologic malignancies, while discontinuing LAVA-1207 development. The company will continue supporting partnered programs with Pfizer and Johnson & Johnson. Key Q4 developments include initiation of LAVA-1266 Phase 1 trial and a $5.0M milestone payment from J&J.Financial highlights: Cash position of $78.9M as of September 30, 2024, with runway extended into 2027. Q3 2024 showed net losses of $12.3M ($0.46 per share) compared to $8.8M ($0.34 per share) in Q3 2023. Research and development expenses increased to $8.5M from $7.9M year-over-year.

#LVTX LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

#news #StockMarket #investing

www.stocktitan.net/news/LVTX/lava-reports-t...